Subclinical hypothyroidism: Comparison of adhesion molecule levels before and after levothyroxine therapy

Simple item page
dc.contributor.authorBilgir F.
dc.contributor.authorBilgir O.
dc.contributor.authorCalan M.
dc.contributor.authorCalan O.
dc.contributor.authorIsikyakar T.
dc.date.accessioned2024-07-22T08:16:54Z
dc.date.available2024-07-22T08:16:54Z
dc.date.issued2014
dc.description.abstractObjective: Adhesion molecules are involved in inflammation, atherosclerosis and malignancy. This study measured levels of adhesion molecules before and after levothyroxine therapy in patients with subclinical hypothyroidism (SHO). Methods: Levels of soluble (s) intracellular adhesion molecule (ICAM)-1, s vascular cell adhesion molecule (sVCAM) VCAM-1 and sE-selectin were analysed in patients diagnosed with SHO, prior to administration of 50 mg/day levothyroxine orally for 3 months. Subsequently, levels of sICAM-1, sVCAM-1 and sE-selectin were reanalysed then compared with the pretreatment levels. Results: In 30 patients with SHO, levels of sICAM-1 were found to be significantly higher than those in healthy controls, (P=0.001). Post-treatment sICAM-1 levels were significantly lower than pretreatment levels (P=0.001). No significant differences were found in sVCAM-1 or sE-selectin levels between healthy controls and patients with SHO before treatment, or between patients with SHO pre- and post-treatment. Conclusions: Patients with SHO had significantly higher levels of sICAM-1 compared with controls. Levels became normal after treatment with levothyroxine. These findings emphasize the need for levothyroxine therapy in cases of SHO to normalize sICAM-1 levels. Such treatment helps to prevent the future development of atherosclerosis or cancer. © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
dc.identifier.DOI-ID10.1177/0300060514526566
dc.identifier.issn03000605
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16912
dc.language.isoEnglish
dc.publisherSAGE Publications Ltd
dc.subjectAdult
dc.subjectAsymptomatic Diseases
dc.subjectCase-Control Studies
dc.subjectDrug Administration Schedule
dc.subjectE-Selectin
dc.subjectFemale
dc.subjectHumans
dc.subjectHypothyroidism
dc.subjectIntercellular Adhesion Molecule-1
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectThyrotropin
dc.subjectThyroxine
dc.subjectTreatment Outcome
dc.subjectTriiodothyronine
dc.subjectVascular Cell Adhesion Molecule-1
dc.subjectendothelial leukocyte adhesion molecule 1
dc.subjectintercellular adhesion molecule 1
dc.subjectlevothyroxine
dc.subjectliothyronine
dc.subjectthyrotropin
dc.subjectthyroxine
dc.subjectvascular cell adhesion molecule 1
dc.subjectendothelial leukocyte adhesion molecule 1
dc.subjectICAM1 protein, human
dc.subjectintercellular adhesion molecule 1
dc.subjectliothyronine
dc.subjectthyrotropin
dc.subjectthyroxine
dc.subjectvascular cell adhesion molecule 1
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectfatigue
dc.subjectfemale
dc.subjectfree thyroxine index
dc.subjectHashimoto disease
dc.subjecthuman
dc.subjectimmunoassay analyzer
dc.subjectliothyronine blood level
dc.subjectmale
dc.subjectmorbidity
dc.subjectsubclinical hypothyroidism
dc.subjectthyrotropin blood level
dc.subjecttreatment duration
dc.subjectweight gain
dc.subjectasymptomatic disease
dc.subjectblood
dc.subjectcase control study
dc.subjectdrug administration
dc.subjecthypothyroidism
dc.subjectmiddle aged
dc.subjecttreatment outcome
dc.titleSubclinical hypothyroidism: Comparison of adhesion molecule levels before and after levothyroxine therapy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu